Metastatic pancreatic cancer: American Society of Clinical Oncology clinical practice guideline

Journal of Clinical Oncology

Volumn 34, Issue 23, 2016, Pages 2784-2796

  Sohal, Davendra P S ^a   Mangu, Pamela B ^b   Khorana, Alok A ^a   Shah, Manish A ^c   Philip, Philip A ^d   O'Reilly, Eileen M ^f   Uronis, Hope E ^h   Ramanathan, Ramesh K ⁱ   Crane, Christopher H ^k   Engebretson, Anitra ^l   Ruggiero, Joseph T ^g   Copur, Mehmet S ^m   Lau, Michelle ^j   Urba, Susan ^e   Laheru, Daniel ⁿ  

^a LERNER RESEARCH INSTITUTE   (United States)

^b AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^c WEILL CORNELL MEDICAL CENTER   (United States)

^d KARMANOS CANCER INSTITUTE   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

^h DUKE UNIVERSITY   (United States)

ⁱ MAYO CLINIC   (United States)

^j Community Hospital Based Cancer Center ^*  (United States)

^k UNIVERSITY OF TEXAS   (United States)

^l Patient Representative   (United States)

^m Saint Francis Medical Center Grand Island   (United States)

ⁿ JOHNS HOPKINS UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ANALGESIA; ANOREXIA; ANXIETY; ASCITES; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; CHOLESTASIS; CHRONIC DISEASE; COMORBIDITY; DEPRESSION; DISEASE COURSE; DISEASE FREE SURVIVAL; DOCTOR PATIENT RELATION; DUODENUM OBSTRUCTION; HEALTH CARE COST; HEALTH DISPARITY; HISTOPATHOLOGY; HUMAN; METASTATIC PANCREATIC CANCER; OVERALL SURVIVAL; PALLIATIVE THERAPY; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PATIENT PREFERENCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; WEIGHT REDUCTION; CARCINOMA, PANCREATIC DUCTAL; DIAGNOSTIC IMAGING; EVIDENCE BASED MEDICINE; INTERPERSONAL COMMUNICATION; PANCREATIC NEOPLASMS; PATHOLOGY; PATIENT CARE; PATIENT CARE PLANNING; SECONDARY; SYMPTOM ASSESSMENT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, PANCREATIC DUCTAL; COMMUNICATION; EVIDENCE-BASED MEDICINE; HUMANS; PAIN MANAGEMENT; PALLIATIVE CARE; PANCREATIC NEOPLASMS; PATIENT CARE PLANNING; PATIENT CARE TEAM; SYMPTOM ASSESSMENT;

EID: 84981171236     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.67.1412     Document Type: Review

References (66)

1. American Cancer Society: Cancer facts & figures 2015. www.cancer.org/acs/groups/content/@ editorial/documents/document/acspc-044552.pdf
2. World Cancer Research Fund International: Pancreatic cancer statistics. www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/pancreatic-cancer-statistics
3. Rahib L, Smith BD, Aizenberg R, et al: Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74:2913-2921, 2014
4. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2006. CA Cancer J Clin 56:106-130, 2006
5. American Cancer Society: Cancer facts & figures 2013. www.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2013
6. Malvezzi M, Bertuccio P, Levi F, et al: European cancer mortality predictions for the year 2013. Ann Oncol 24:792-800, 2013
7. Hawes RH, Xiong Q, Waxman I, et al: A multispecialty approach to the diagnosis and management of pancreatic cancer. Am J Gastroenterol 95:17-31, 2000
8. Conroy T, Desseigne F, Ychou M, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817-1825, 2011
9. Von Hoff DD, Ervin T, Arena FP, et al: Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691-1703, 2013
10. Sohal DP, Walsh RM, Ramanathan RK, et al: Pancreatic adenocarcinoma: Treating a systemic disease with systemic therapy. J Natl Cancer Inst 106: dju011, 2014
11. Rhim AD, Mirek ET, Aiello NM, et al: EMT and dissemination precede pancreatic tumor formation. Cell 148:349-361, 2012
12. Shiffman RN, Michel G, Rosenfeld RM, et al: Building better guidelines with BRIDGE-Wiz: Development and evaluation of a software assistant to promote clarity, transparency, and imple-mentability. J Am Med Inform Assoc 19:94-101, 2012
13. Oettle H, Riess H, Stieler JM et al: Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: Outcomes from the CONKO-003 trial. J Clin Oncol 32:2423-2429, 2014
14. Rougier P, Riess H, Manges R, et al: Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer. Eur J Cancer 49:2633-2642, 2013
15. Gonçalves A, Gilabert M, François E, et al: BAYPAN study: A double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Ann Oncol 23:2799-2805, 2012
16. Kindler HL, Ioka T, Richel DJ, et al: Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: A double-blind randomised phase 3 study. Lancet Oncol 12:256-262, 2011
17. Da Cunha Santos G, Dhani N, Tu D, et al: Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3. Cancer 116:5599-5607, 2010
18. Moinpour CM, Vaught NL, Goldman B, et al: Pain and emotional well-being outcomes in Southwest Oncology Group-directed intergroup trial S0205: a phase III study comparing gemcitabine plus cetux-imab versus gemcitabine as first-line therapy in patients with advanced pancreas cancer. J Clin Oncol 28:3611-3616, 2010
19. Colucci G, Labianca R, Di Costanzo F, et al: Randomized phase III trial of gemcitabine plus cis-platin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: The GIP-1 study. J Clin Oncol 28:1645-1651, 2010
20. Dahan L, Bonnetain F, Ychou M, et al: Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: Final results of a randomised strategic phase III trial (FFCD 0301). Gut 59:1527-1534, 2010
21. Cunningham D, Chau I, Stocken DD, et al: Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 27:5513-5518, 2009
22. Van Cutsem E, Vervenne WL, Bennouna J, et al: Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with meta-static pancreatic cancer. J Clin Oncol 27:2231-2237, 2009
23. Poplin E, Feng Y, Berlin J, et al: Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: A trial of the Eastern Cooperative Oncology Group. J Clin Oncol 27:3778-3785, 2009
24. Bernhard J, Dietrich D, Scheithauer W, et al: Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: A randomized multicenter phase III clinical trial-SAKK 44/00-CECOG/PAN.1.3.001. J Clin Oncol 26:3695-3701, 2008
25. Herrmann R, Bodoky G, Ruhstaller T, et al: Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: A randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 25:2212-2217, 2007
26. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcita-bine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966, 2007
27. Abou-Alfa GK, Letourneau R, Harker G, et al: Randomized phase III study of exatecan and gem-citabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol 24:4441-4447, 2006
28. Stathopoulos GP, Syrigos K, Aravantinos G, et al: A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer 95:587-592, 2006
29. Heinemann V, Quietzsch D, Gieseler F, et al: Randomized phase III trial of gemcitabine plus cis-platin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 24:3946-3952, 2006
30. Reni M, Cordio S, Milandri C, et al: Gemcita-bine versus cisplatin, epirubicin, fluorouracil, and gem-citabine in advanced pancreatic cancer: A randomised controlled multicentre phase III trial. Lancet Oncol 6:369-376, 2005
31. Louvet C, Labianca R, Hammel P, et al: Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: Results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23:3509-3516, 2005
32. Rocha Lima CM, Green MR, Rotche R, et al: Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 22:3776-3783, 2004
33. Berlin JD, Catalano P, Thomas JP, et al: Phase III study of gemcitabine in combination with fluo-rouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20:3270-3275, 2002
34. Maisey N, Chau I, Cunningham D, et al: Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer. J Clin Oncol 20:3130-3136, 2002
35. Goldstein D, El-Maraghi RH, Hammel P, et al: nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: Long-term survival from a phase III trial. J Natl Cancer Inst 107:107, 2015
36. Pawlik TM, Laheru D, Hruban RH, et al: Evaluating the impact of a single-day multidisciplinary clinic on the management of pancreatic cancer. Ann Surg Oncol 15:2081-2088, 2008
37. Hoos WA, James PM, Rahib L, et al: Pancreatic cancer clinical trials and accrual in the United States. J Clin Oncol 31:3432-3438, 2013
38. Ma C, Bandukwala S, Burman D, et al: Inter-conversion of three measures of performance status: An empirical analysis. Eur J Cancer 46:3175-3183, 2010
39. Mahaseth H, Brutcher E, Kauh J, et al: Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarci-noma. Pancreas 42:1311-1315, 2013
40. Wang-Gillam A, Li CP, Bodoky G, et al: Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): A global, randomised, open-label, phase 3 trial. Lancet 387:545-557, 2016
41. Burris HA III, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15:2403-2413, 1997
42. Rahma OE, Duffy A, Liewehr DJ, et al: Second-line treatment in advanced pancreatic cancer: A comprehensive analysis of published clinical trials. Ann Oncol 24:1972-1979, 2013
43. Morrison RS, Augustin R, Souvanna P, et al: America's care of serious illness: a state-by-state report card on access to palliative care in our nation's hospitals. J Palliat Med 14:1094-1096, 2011
44. Kelley AS, Morrison RS: Palliative care for the seriously ill. N Engl J Med 373:747-755, 2015
45. Seicean A: Celiac plexus neurolysis in pancreatic cancer: The endoscopic ultrasound approach. World J Gastroenterol 20:110-117, 2014
46. Wong GY, Schroeder DR, Carns PE, et al: Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unre-sectable pancreatic cancer: A randomized controlled trial. JAMA 291:1092-1099, 2004
47. Amr YM, Makharita MY: Neurolytic sym-pathectomy in the management of cancer pain-time effect: A prospective, randomized multicenter study. J Pain Symptom Manage 48:944-956, 2014
48. Damerla V, Gotlieb V, Larson H, et al: Pancreatic enzyme supplementation in pancreatic cancer. J Support Oncol 6:393-396, 2008
49. Bruno MJ, Haverkort EB, Tijssen GP, et al: Placebo controlled trial of enteric coated pancreatin microsphere treatment in patients with unresectable cancer of the pancreatic head region. Gut 42:92-96, 1998
50. Boulay BR, Parepally M: Managing malignant biliary obstruction in pancreas cancer: Choosing the appropriate strategy. World J Gastroenterol 20:9345-9353, 2014
51. Baron TH: Expandable metal stents for the treatment of cancerous obstruction of the gastrointestinal tract. N Engl J Med 344:1681-1687, 2001
52. Maire F, Hammel P, Ponsot P, et al: Long-term outcome of biliary and duodenal stents in palliative treatment of patients with unresectable adeno-carcinoma of the head of pancreas. Am J Gastro-enterol 101:735-742, 2006
53. Khorana AA, Ahrendt SA, Ryan CK, et al: Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res 13:2870-2875, 2007
54. Khorana AA: Venous thromboembolism and prognosis in cancer. Thromb Res 125:490-493, 2010
55. Khorana AA, Francis CW, Culakova E, et al: Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 5:632-634, 2007
56. Lyman GH, Bohlke K, Khorana AA, et al: Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014. J Clin Oncol 33:654-656, 2015
57. Maraveyas A, Waters J, Roy R, et al: Gem-citabine versus gemcitabine plus dalteparin throm-boprophylaxis in pancreatic cancer. Eur J Cancer 48:1283-1292, 2012
58. Vadhan-Raj S, Zhou X, Benjamin RS, et al: Incidence and risk factors predictive of recurrent venous thromboembolism in patients with cancer at a comprehensive cancer center. J Clin Oncol 29, 2011(suppl, abstr 9059)
59. Epstein RMSR, Jr. Patient-Centered Communication in Cancer Care: Promoting Healing and Reducing Suffering. Bethesda, MD, National Cancer Institute, 2007
60. Mead H, Cartwright-Smith L, Jones K, et al: Racial and Ethnic Disparities in U. S. Health Care: A Chartbook. New York, NY, Commonwealth Fund, 2008
61. Lee S, Reha JL, Tzeng CW, et al: Race does not impact pancreatic cancer treatment and survival in an equal access federal health care system. Ann Surg Oncol 20:4073-4079, 2013
62. Dias-Santos D, Ferrone CR, Zheng H, et al: The Charlson age comorbidity index predicts early mortality after surgery for pancreatic cancer. Surgery 157:881-887, 2015
63. Hurria A, Togawa K, Mohile SG, et al: Predicting chemotherapy toxicity in older adults with cancer: A prospective multicenter study. J Clin Oncol 29:3457-3465, 2011
64. Attard CL, Brown S, Alloul K, et al: Cost-effectiveness of FOLFIRINOX for first-line treatment of metastatic pancreatic cancer. Curr Oncol 21:e41-e51, 2014
65. Chiorean EG, Whiting S, Binder G, et al: Cost-effectiveness of nab-paclitaxel plus gemcitabine versus erlotinib plus gemcitabine in metastatic pancreatic cancer. J Clin Oncol 32, 2014(suppl, abstr 353)
66. Abbruzzese JL, Hess KR: New option for the initial management of metastatic pancreatic cancer? J Clin Oncol 32:2405-2407, 2014